INTRODUCTION
Fabry Disease (FD; OMIM:301500) is a rare X-linked lysosomal storage disorder caused by deficient activity of -galactosidase A enzyme (α-GAL A) (DESNICK RJ, et al., 2001 ). The reason that leads to the deficiency of the enzymatic activity is due to the existence of several mutations that occur in the GLA gene that affect the synthesis, processing, and the stability of α-GAL A (LEMANSKY P, et al., 1987).
The defective enzyme leads the progressive accumulation of glycosphingolipids, especially globotriaosylceramide (Gb3) and lyso-Gb3, in plasma and in a wide range of cell types throughout the body inducing inflammatory processes, ischemia, hypertrophy and the development of fibrosis. (MEHTA A and HUGHES DA, 2017).
The prevalence of FD is estimated to be between 0.85 and 2.5 cases per 100,000 inhabitants worldwide, however this estimate may be underestimated due to the different clinical forms preformed by Fabry disease, making it possibly an underreported disease. (MEHTA A, et al., 2004) .
Depending on the α-Gal A activity, in addition to other factors, Fabry disease may present several forms of clinical manifestation, ranging from the apparently asymptomatic form observed occasionally in females to the classic severe phenotype in males (MEHTA A, et al., 2009 ).
Like the most lysosomal disorders, FD is a systemic disease, with a wide spectrum of clinical manifestations mainly affecting the heart, the central nervous system (CNS), and the kidneys (MEHTA A and HUGHES DA, 2017). Among clinical manifestations of FD, Fabry nephropathy (FN) is one of the most severe manifestations of FD and was the cause of death before the widespread availability of enzymatic replacement therapy (ERT). Frequently, patients with no family history of FD are first diagnosed by a nephrologist during investigation of Chronic Renal Disease (CKD) with unknown etiology through renal biopsy. Glomerular sclerosis and tubulointerstitial fibrosis are the histological features that best correlate with the progression of FN in humans (VALBUENA C, et al., 2008).
Like most aspects of FD, kidney disease is thought to result from Gb3 accumulation in glomerular endothelial, mesangial and interstitial cells, podocytes and renal vasculature. Deposition of Gb3 and lysoGb3 can promote vascular smooth muscle cell proliferation and the release of mediators of glomerular injury such as TGF-β, a critical mediator of extracellular matrix production (ECM), fibrosis and podocyte lesion (SANCHEZ-NIÑO MD, et al., 2011).
Podocyte injury is the primary factor in the progression of CKD (ICHIKAWA MA, et al., 2005) and in the FD context the Gb3 accumulation in podocytes start in early childhood (TONDEL C, et al., 2008) . Podocyte injury causes shortening of the primary and secondary podocytes processes that bind it to the glomerular basement membrane (GBM), an effect known as podocyte effacement, leading to tearing of the podocyte that is excreted in the urine. With the initial loss of podocytes, the remaining podocytes responded by compensatory hypertrophy. However, continuous loss of podocytes is cumulative, and the remaining podocytes become unable to compensate for the lost cells, resulting in sclerosis of the entire glomerulus (KRIZ W, et al., 2013).
Other factors considered to be involved in the pathophysiology are the rupture of the lysosome (PLATT FM, et al., 2012) and damage due to local inflammation, activation of pro-apoptotic pathways and destruction of the podocytes by cytotoxic mechanisms, showing the role of the immune system in the pathophysiology of FD (MAUHIN W, et al., 2015) .
Besides, Gb3 accumulation may alter the nature of cell membranes, e.g. lymphocyte cell membranes, resulting in a change in the cell surface signaling, gene regulation, and subsequent protein expression, creating an environment capable of providing autoimmune responses. This observation corroborates what is known about defects in immune cells in systemic lupus erythematosus (SLE) patients, where the composition of lipids in the lymphocyte cell membranes is altered (including Gb3) and may lead to an increase in the activation of these pathways (JURY EC, et al., 2007).
As the role of GB3 accumulation in the development of autoimmune disease has not yet been elucidated, it becomes another challenge for diagnosis, since the patient presents a hereditary disease difficult to diagnose and sometimes asymptomatic (FD), but requires attention to the manifestations of autoimmune diseases, leaving the professional the difficult task of defining whether is an association of diseases or DF only. Some cases have already been reported from patients with FD associated with other glomerular diseases, e.g., lupus nephritis, thin basement membrane nephropathy, crescentic glomerulonephritis, immunoglobulin A nephropathy, and rheumatoid arthritis-associated renal diseases (LIU Y, et al., 2016).
Here, we will describe two cases of FD of a family nucleus one associated with membranous nephropathy (MN) and another with SLE.
CASE REPORT Case 01
A 61-year-old man arrived at the hospital in 2014 with clinical status of nephrotic syndrome. Previously, he had been diagnosed with cardiomyopathy and had been using beta-blockers continuously.
He did not report any family history of genetic diseases, diabetes mellitus, infectious diseases, and/or neoplasias. However, he had a daughter diagnosed with SLE.
The physical examination showed that the patient was normotensive and had generalized nephrotic-like edema, whereas complementary laboratory examinations for viral and neoplasia diseases were negative.
A complementary immunohistochemical study carried out in recovered kidney tissue biopsy from paraffin blocks revealed scarce deposits of anti-phospholipase A2 antibodies (anti-PLA2) and IgG4 GBM. The presence of anti-PLA2 antibodies was also confirmed in the peripheral blood, as per results (ratio of 3.84) of ELISA assays (EUROIMMUN, Lübeck, Germany).
In the kidney function evaluation and biochemical parameters, the patient exhibited nephrotic proteinuria (7g/24 hours), hypoalbuminemia (2.2g/dL), dyslipidemia, and a measured Glomerular Filtration Rate (GFR) of 72.6 ml/min/1.73m². Given the suspicion that the patient had FD, complementary examinations were requested to help diagnosis. Table 1 shows that the patient presented accumulation of lyso-GB3, with an important reduction of the enzymatic activity of the α-GAL A enzyme and Fabry Disease manifestations in organs and tissues such as heart and cornea. With laboratory and genomic findings compatible with FD associated with primary MN, the Enzyme Replacement Therapy (ERT) was started with agalsidase alfa (Replagal®, Shire Human Genetic Therapies, Cambridge, MA, USA) in recommended doses and intervals, associated with the blockage of the angiotensin II receptor.
The exonic and splicing regions sequencing of the GLA gene allowed the identification of a pathogenic hemizygous mutation in the exon 7 c.1046G>C p.W349S. After confirmation of the mutation in the proband and the family member's consent, a family screening to detect the mutation in the GLA gene was performed. The screening result allowed to make a pedigree with 29 individuals distributed in five generations. Except for the first generation, all the others had affected individuals in both genders, being four males and seven females (Figure 2) . (Figure 3-A) ; reduction of the 24h proteinuria values (Figure 3-B) ; and an increase of estimated Glomerular Filtration Rate (eGFR) (Figure 3-C) . Although proteinuria remains at a high level (2.4g/24h), the patient recovered plasma albumin and re-balanced the intravascular with the disappearance of the edemigenic status. The concentration of lyso-Gb3 after 24 months of ERT was 12.3 ng/mL, and the cardiac magnetic resonance showed a small fibrosis area in the left ventricular corresponding to 1% of its total mass. 
CASE 02
The fact that FD is a chromosome X-linked pathology tells us that any daughter of an affected man will necessarily be a carrier of the disease. Thus, with the support of this rationale and based upon the pedigree (Figure 2 ) attained from the familial screening, we evaluated the daughter (IV-3) of the index case (III-1) as for the clinical history and the presence of the familial mutation in the GLA gene. The exonic sequencing of the GLA gene confirmed the presence of the pathogenic mutation c.1046G>C p.W349S in the exon 7, whose phenotypical effect was ratified by the serum concentration of lyso-Gb3 (2.2ng/mL). Together, these findings confirmed FD in the daughter of the index case.
The patient's clinical history also showed that she was a carrier of SLE using azathioprine and hydroxychloroquine. Complementary examinations to diagnose FD identified the presence of cornea verticillata and alterations in the magnetic resonance, such as microgliosis. Kidney evaluation showed GFR of 100ml/min/1.73m 2 , proteinuria of 800 mg/24h, and hematuria in the urinalysis. Kidney biopsy was indicated, and the histologic findings exhibited class V lupus nephritis. At the EM lipid deposits were observed in the cytoplasm of podocytes and effacement of pedicles (Figure 4) . The complementary immunohistochemical study revealed negativity in the GBM for the anti-PLA2 and IgG4 antibodies. The findings confirmed a coexistence of FD and an autoimmune disease, the patient started the ERT with agalsidase alfa, was encouraged to visit a rheumatologist, and to discontinue the use of hydroxychloroquine.
DISCUSSION
Here we describe a rare coincidence of two patients with FD in the same family associated, one with primary glomerulonephritis (GN) and the other with secondary GN related to SLE.
The accumulation of the Gb3 substrate in lysosomes and cell cytoplasm is not inert and interferes in the function of different cells, including those of the immune system, causing chronic stimulation of their components (MAUHIN W, et al., 2015) .
Several case reports show coexistence of Fabry Disease and glomerular diseases, with IgA Nephropathy (IgAN) being the most frequent (MAIXNEROVÁ D, et al., 2013; WHYBRA C, et al., 2006) . Whether FD has an activator role in the IgAN remains unclear. However, it has been shown that the accumulation of glycosphingolipids can induce an autoimmune response (HAMERS MN, et al., 1978) , and in an animal, model glomerulonephritis was induced by a structurally similar molecule to Gb3 (SHIBATA, S et al., 1988) .
The occurrence of FD with other GN by IC are rare events from whose studies answers may arise for unfathomable essential questions, e.g. (1) Is the molecular mimicry a necessary condition for the coexistence of both pathologies? (2) Is the accumulated Gb3 able to trigger responses from autoantibodies? The answers to these questions are of great relevance as they will provide the basis for managing the factors that potentiate the formation of immune complexes in genetically susceptible individuals.
In Case 1, the patient has a rare association of autoimmune disease and FD. The coloration by immunohistochemistry confirmed the IC against an endogenous antigen to PLA2. Although the tissue coloration has been poor, the level of the serum anti-PLA2 antibody was high, confirming thus the primary GN involving the immunoglobulin IgG4-complexed PLA2 podocyte antigen. Hence, this patient exhibits a double injury to the podocyte: by the chronic and progressive accumulation of Gb3, with later complementdependent cytotoxicity, and by the dysfunction of the PLA2 receptor in the podocyte's membrane.
In recent research, Seitz-Polski B et al. (2016) suggested that the development of primary MN depends on mimicry of microbial and environmental antigens with PLA2 protein. However, the fact of the PLA2 receptor being low-expressive in the podocytes' membrane and, therefore, little access to circulating T-cells, minimize the chances of this being the inducer of the autoimmune response in the cases herein. This leads us to question whether -in FD -Gb3 can be a metabolic trigger for autoimmunity in families susceptible to such diseases, as in FD there is a chronic and increasing accumulation of Gb3 in podocytes to start from the kidney embryogenesis (BRADY RO, et al., 1971 ).
Actually, the Gb3-impregnated podocytes occur very early, as proved by Najafian B et al. (2011) , by publishing that podocytes are the most attacked cells in children, carriers of FD, in the absence of microalbuminuria, and/or alteration of GFR. Tøndel C et al. (2013) observed that the early use of ERT in the population studied could reverse the EP-like histologic damages leading to the clearance of podocyte deposits.
In case 2, there is the association of FD and SLE. Though rare this association, it is believed to be underdocumented, regarding that FD is a rare and less symptomatic disease in women and, therefore, greatly delays diagnosis, which occurs on average in the 3rd or 4 th decade of their lives. Contrariwise, SLE is very frequent in women usually in their second decade of life, corroborating our case, whose SLE diagnosis precedes that of Fabry in a decade. The accumulation of Gb3 causes changes in the lymphocyte cell membranes enabling a favorable environment for autoimmune disease. Martinez and collaborators evaluated the prevalence of anti-extractable nuclear antigens in FD patients finding the positivity of at least one antibody in 57% of patients (MARTINEZ P, et al., 2007).
Although impregnation of podocytes by Gb3 is a characteristic finding of Fabry nephropathy, it is not pathognomonic. Thence, the analysis of histologic findings is necessary for the light of clinical, laboratory, and genetic knowledge for a differential diagnosis. Drug-induced impregnation is dose-dependent and reversible with its interruption, as recently shown by de Menezes Neves PDM et al. (2017) . In case 2, the patient had been using chloroquine since the diagnosis of SLE, but she was a mandatory carrier of the mutation, as she is a daughter of the index case. Chloroquines are widely known as inducers of lysosomal enzymes dysfunction, responsible for the degradation of lipid substrates in lysosomes (DONG H and CZAJA MJ, 2011).
Therefore, the use of chloroquine by FD carriers must be given in-depth consideration, with the risk of potentiating the accumulation of podocyte Gb3, accelerating podocyturia, albuminuria, and loss of kidney function. With this rationale in mind, Case 2 of this study was discussed with a rheumatologist over the risks and benefits of discontinuing the use of adjuvant chloroquine in the treatment of SLE, regarding it as an additional factor for the accumulation of Gb3 in the different cells of the organism.
Lastly, the importance of the kidney biopsy is pointed out in the cases reported here. Systematic histologic examination of kidney biopsy specimens not only confirmed the preliminary diagnosis of membranous nephropathy, but also provided evidence indicative of Fabry nephropathy, leading to identification of Fabry disease in the proband and his family members, allowing early diagnosis and genetic counseling on a hereditary disease with a still late diagnosis with severe complications in organs such as kidney, heart, and the CNS.
